SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline

 SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline

SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline

Shots:

  • The acquisition expands SparingVision’s ocular genomic medicine pipeline with the addition of GAMUT’s lead product SPVN20, which is a novel, mutation-agnostic gene therapy, focuses on restoring the function of dormant cone cells in the retina. The acquisition is expected to close in Q2’21
  • SparingVision plans to evaluate the therapeutic synergy with a combination of both products (SPVN06 and SPVN20) addressing both mid & late stages of rod-cone dystrophies in patients with RP
  • Additionally, SparingVision will explore SPVN20 in other retinal diseases and has the right to participate in the creation of a new GIRK-based cell therapy company

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post